BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
 

Nanosphere Inc. Awarded Two NIH Grants to Assess Genetic Risk Factors for Cancer and Hypercoagulation Disorders

Northbrook, IL-- September 17, 2002 -- Nanosphere Inc., a privately held nanotechnology-based life sciences company, announced today it has been awarded two grants from the National Institutes of Health (NIH) totaling $1.5 million.  These grants will fund the development of SNP molecular diagnostic tests to assess genetic risk factors for hypercoagulation disorders and colorectal cancer.

The first NIH grant is focused on the development of a hypercoagulation disorder panel consisting of SNPs in three genes (factor V, prothrombin, and MTHFR).  This panel is to be performed without target amplification (i.e. PCR) on Nanosphere’s automated detection system.  Colorectal cancer SNPs are the focus of the second NIH grant and also will be performed on the company’s system with a simplified target preparation, hybridization and detection protocol.

 "Nanosphere is pleased to be the recipient of these grants, and the timing for the development of these tests coincides perfectly with the release of our detection system geared toward the clinical diagnostic market," said Vijaya Vasista, Nanosphere's Chief Operating Officer.  "The ability to test for coagulation disorders and propensity for colorectal cancer demonstrates the breadth of tests that can be performed on Nanosphere’s system,” she added.

The company's ultra sensitive detection platform is designed to eliminate traditional amplification methods, such as PCR.  Nanosphere's platform utilizes its well-published nanoparticle probe technology in conjunction with a proprietary bio-molecular detection system that exhibits extraordinary sensitivity while demonstrating 100,000 times greater specificity than current genomic detection systems.

Nanosphere, a venture capital-backed company, is a nanotechnology-based life sciences company in Northbrook, Illinois that is focused on developing assays for research, clinical and point-of-care detection markets.  For more information, visit the company's web site at http://www.nanosphere-inc.com.

###

Wendy Emanuel
Principal
Wellspring Communications, Inc.
2520 North Sheffield Avenue, Suite Q
Chicago, Illinois  60614
773-665-7650

wendy@wellspringcom.com 

http://www.wellspringcom.com 

 
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.